GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » EPS (Diluted)

Zydus Lifesciences (BOM:532321) EPS (Diluted) : ₹42.66 (TTM As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences EPS (Diluted)?

Zydus Lifesciences's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was ₹9.06. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹42.66.

Zydus Lifesciences's EPS (Basic) for the three months ended in Sep. 2024 was ₹9.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹42.66.

Zydus Lifesciences's EPS without NRI for the three months ended in Sep. 2024 was ₹9.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was ₹41.47.

During the past 12 months, Zydus Lifesciences's average EPS without NRIGrowth Rate was 62.30% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 16.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Zydus Lifesciences's highest 3-Year average EPS without NRI Growth Rate was 43.00% per year. The lowest was -73.00% per year. And the median was 10.65% per year.


Zydus Lifesciences EPS (Diluted) Historical Data

The historical data trend for Zydus Lifesciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences EPS (Diluted) Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.49 20.84 43.83 19.30 38.14

Zydus Lifesciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.91 7.80 11.69 14.11 9.06

Competitive Comparison of Zydus Lifesciences's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's PE Ratio falls into.



Zydus Lifesciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Zydus Lifesciences's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as

Diluted EPS (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(38595-0)/1011.927
=38.14

Zydus Lifesciences's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(9112-0)/1005.740
=9.06

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹42.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zydus Lifesciences  (BOM:532321) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Zydus Lifesciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.

Zydus Lifesciences Headlines

No Headlines